Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Interest Expenses (2022 - 2023)

Candel Therapeutics' Interest Expenses history spans 2 years, with the latest figure at $673000.0 for Q4 2023.

  • For Q4 2023, Interest Expenses rose 16.44% year-over-year to $673000.0; the TTM value through Dec 2023 reached $2.6 million, up 136.55%, while the annual FY2024 figure was -$2.1 million, 180.54% down from the prior year.
  • Interest Expenses for Q4 2023 was $673000.0 at Candel Therapeutics, up from $669000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $673000.0 in Q4 2023 and bottomed at $519000.0 in Q3 2022.